1. Volume 13, Issue 5, Pages 476-486 (May 2012)
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial 
Prof Garnet L Anderson, PhD, Prof Rowan T Chlebowski, MD, Aaron K Aragaki, MS, Prof Lewis H Kuller, MD, Prof JoAnn E Manson, MD, Prof Margery Gass, MD, Elizabeth Bluhm, MD, Prof Stephanie Connelly, MD, Prof F Allan Hubbell, MD, Prof Dorothy Lane, MD, Lisa Martin, MD, Prof Judith Ockene, PhD, Prof Thomas Rohan, MBBS, Prof Robert Schenken, MD, Prof Jean Wactawski-Wende, PhD 
The Lancet Oncology 
Volume 13, Issue 5, Pages (May 2012)
DOI: /S (12)70075-X
Copyright © 2012 Elsevier Ltd Terms and Conditions

2. Figure 1
Kaplan-Meier estimates of cumulative hazards of invasive breast cancer in the WHI randomised trial of conjugated equine oestrogen with the intention-to-treat principle (A) and with adjustments for adherence (B)
Background shading shows the distribution of the duration of intervention (in quintiles). HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (12)70075-X)
Copyright © 2012 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier estimates of cumulative hazards for breast cancer deaths (A) and all-cause mortality after breast cancer (B) in the WHI randomised trial of conjugated equine oestrogen
Background shading shows the distribution of the duration of intervention (in quintiles). HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (12)70075-X)
Copyright © 2012 Elsevier Ltd Terms and Conditions

4. Figure 3
Hazard ratios for invasive breast cancer incidence by baseline characteristics in the WHI trial of conjugated equine oestrogen
Data are n (% per year) unless otherwise stated.
The Lancet Oncology  , DOI: ( /S (12)70075-X)
Copyright © 2012 Elsevier Ltd Terms and Conditions

5. Figure 4
Cumulative hazards, adjusted for age and ethnic group, of invasive breast cancer by random allocation in the WHI trials of conjugated equine oestrogen alone and conjugated equine oestrogen plus medroxyprogesterone acetate trials derived from Chlebowski and colleagues32
HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (12)70075-X)
Copyright © 2012 Elsevier Ltd Terms and Conditions